Evidence map›Paper›PMID 28938567›Full record

ArticleOncotarget2017

Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling.

Jin-Wen Song, Ying-Xia Tan, Su-Bo Li, Shi-Kun Zhang, Lu-Ming Wan, Shou-Ping Ji, Hong Zhou, Zhi-Hang Zhou, Feng Gong

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Heparanase, cell signaling, and viral infections.Cellular and molecular life sciences : CMLS · 2020
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jin-Wen SongDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Ying-Xia TanDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Su-Bo LiDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Shi-Kun ZhangDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Lu-Ming WanDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Shou-Ping JiDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Hong ZhouDepartment of Blood Products and Substitutes, Beijing Institute of Transfusion Medicine, Beijing, China.
Zhi-Hang ZhouDepartment of Pathology, The 309th Hospital of People's Liberation Army, Beijing, China.
Feng GongDepartment of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
Guangzhou Blood Center · CNThe 309th Hospital of Chinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC), characterized by aggressive local invasion and metastasis, is one of the most malignant cancers. Gemcitabine is currently used as the standard drug for the treatment of advanced and metastatic PC, but with limited efficacy. In this study, we demonstrated that gemcitabine increased the expression of heparanase (HPA1), the only known mammalian endoglycosidase capable of cleaving heparan sulfate, both

Indexed as

EGFRgemcitabineHPA1NF-κBpancreatic cancer

Identifiers

PMID28938567
PMCPMC5601663
OpenAlexW2604950140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.